We are live on ! Find out more
FULC icon

Fulcrum Therapeutics

172 hedge funds and large institutions have $763M invested in Fulcrum Therapeutics in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 43 increasing their positions, 49 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

269% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 16

230% more call options, than puts

Call options by funds: $8.87M | Put options by funds: $2.69M

54% more capital invested

Capital invested by funds: $496M → $763M (+$267M)

33% more funds holding

Funds holding: 129172 (+43)

25.18% more ownership

Funds ownership: 99.44%124.62% (+25%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

12% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 49

Holders
172
Holders Change
+43
Holders Change %
+33.33%
% of All Funds
2.09%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
59
Increased
43
Reduced
49
Closed
16
Calls
$8.87M
Puts
$2.69M
Net Calls
+$6.18M
Net Calls Change
+$4.66M
Name Holding Trade Value Shares
Change
Change in
Stake
N
51
Nuveen
North Carolina
$1.27M
Walleye Capital
52
Walleye Capital
New York
$1.23M +$1.1M +108,434 New
UBS Group
53
UBS Group
Switzerland
$1.16M -$2.02M -198,190 -66%
Marshall Wace
54
Marshall Wace
United Kingdom
$1.16M +$1.05M +102,921 New
Ameriprise
55
Ameriprise
Minnesota
$1.14M -$244K -23,991 -19%
MS
56
Maven Securities
Jersey
$1.13M +$1.02M +100,000 New
GCP
57
GSA Capital Partners
United Kingdom
$1.13M -$166K -16,359 -14%
Principal Financial Group
58
Principal Financial Group
Iowa
$1.1M +$317K +31,138 +47%
JF
59
Jump Financial
Illinois
$1.04M +$938K +92,200 New
EAM
60
Exome Asset Management
New York
$1.04M -$68.6K -6,744 -7%
Susquehanna International Group
61
Susquehanna International Group
Pennsylvania
$994K +$350K +34,359 +64%
State of Wisconsin Investment Board
62
State of Wisconsin Investment Board
Wisconsin
$978K +$741K +72,833 +533%
RC
63
RBF Capital
California
$911K
Verition Fund Management
64
Verition Fund Management
Connecticut
$845K +$760K +74,691 New
SCM
65
Superstring Capital Management
New York
$815K +$733K +72,060 New
Citigroup
66
Citigroup
New York
$759K +$676K +66,384 +9,246%
YIH
67
Y-Intercept (HK)
Hong Kong
$755K +$564K +55,444 +492%
LCM
68
Legato Capital Management
California
$750K +$675K +66,347 New
Squarepoint
69
Squarepoint
New York
$745K +$489K +48,026 +269%
T. Rowe Price Associates
70
T. Rowe Price Associates
Maryland
$722K -$21.7K -2,132 -3%
IQI
71
Integrated Quantitative Investments
Washington
$707K +$636K +62,522 New
EI
72
EAM Investors
California
$697K +$627K +61,620 New
AI
73
Atom Investors
Texas
$685K +$617K +60,595 New
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
$653K +$454K +44,625 +341%
RhumbLine Advisers
75
RhumbLine Advisers
Massachusetts
$630K -$139K -13,659 -20%

FULC Hedge Fund Activity: Q4 2025 in Review

172 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2025, worth a combined $763M — up 54% from $496M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new FULC positions and 16 closed out — a net gain of 43 holders — while 43 added to existing stakes and 49 trimmed.

The largest buyer was Braidwell, adding an estimated $28.9M. The largest seller was RA Capital Management, cutting an estimated $42.5M.

  • 172 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2025, up from 129 in Q3 2025.
  • Funds reported $763M of Fulcrum Therapeutics stock for Q4 2025, up 54% quarter-over-quarter.
  • 59 funds opened new Fulcrum Therapeutics positions in Q4 2025 and 16 closed out, a net change of +43 holders.
  • The largest Fulcrum Therapeutics buyer in Q4 2025 was Braidwell, an estimated $28.9M added.
  • The largest Fulcrum Therapeutics seller in Q4 2025 was RA Capital Management, an estimated $42.5M sold.

Based on aggregated 13F filings for Q4 2025.